Century Therapeutics Files 8-K

Ticker: IPSC · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1850119

Sentiment: neutral

Topics: sec-filing, 8-k, regulation-fd

TL;DR

Century Therapeutics filed a standard 8-K on 12/12/25, no major news.

AI Summary

Century Therapeutics, Inc. filed an 8-K on December 12, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this date.

Why It Matters

This 8-K filing indicates routine corporate reporting by Century Therapeutics, Inc. to the SEC, without disclosing any specific new material events or financial performance details.

Risk Assessment

Risk Level: low — The filing is a routine 8-K with no disclosed material events, financial results, or significant corporate actions.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves as a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, and includes a Regulation FD Disclosure and Financial Statements and Exhibits.

What is the exact date of the earliest event reported?

The date of the earliest event reported is December 12, 2025.

What is the company's principal executive office address?

The company's principal executive offices are located at 25 North 38th Street, 11th Floor, Philadelphia, Pennsylvania, 19104.

What is Century Therapeutics, Inc.'s telephone number?

Century Therapeutics, Inc.'s telephone number, including area code, is (267) 817-5790.

What is the SIC code for Century Therapeutics, Inc.?

The Standard Industrial Classification (SIC) code for Century Therapeutics, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

Filing Stats: 545 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-12-12 16:08:14

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure On December 12, 2025, Century Therapeutics, Inc. (the " Company ") updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time. The information contained in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the " Securities Act ") or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit No. Document 99.1 Investor Presentation of Century Therapeutics, Inc., dated December 12, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CENTURY THERAPEUTICS, INC. By: /s/ Brent Pfeiffenberger, PharmD, MBA Name: Brent Pfeiffenberger, PharmD, MBA Title: President and Chief Executive Officer Date: December 12, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing